BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17314754)

  • 1. [Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective].
    Barlési F; Barrau K; Doddoli C; Morange S; Thirion X; Astoul P; Auquier P; Thomas P
    Rev Mal Respir; 2006 Nov; 23(5 Pt 1):489-96. PubMed ID: 17314754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
    Barlesi F; Chouaid C; Crequit J; Le Caer H; Pujol JL; Legodec J; Vergnenegre A; Le Treut J; Fabre-Guillevin E; Loundou A; Auquier P; Simeoni MC; Thomas PA
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):783-90. PubMed ID: 25765952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
    Smit EF; van Meerbeeck JP; Lianes P; Debruyne C; Legrand C; Schramel F; Smit H; Gaafar R; Biesma B; Manegold C; Neymark N; Giaccone G;
    J Clin Oncol; 2003 Nov; 21(21):3909-17. PubMed ID: 14581415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
    Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
    Katakami N; Takiguchi Y; Yoshimori K; Isobe H; Bessho A; Yoshimura A; Niitani H
    J Thorac Oncol; 2006 Jun; 1(5):447-53. PubMed ID: 17409898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
    Neymark N; Lianes P; Smit EF; van Meerbeeck JP
    Pharmacoeconomics; 2005; 23(11):1155-66. PubMed ID: 16277550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
    Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
    Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
    Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
    J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
    Georgoulias V; Ardavanis A; Tsiafaki X; Agelidou A; Mixalopoulou P; Anagnostopoulou O; Ziotopoulos P; Toubis M; Syrigos K; Samaras N; Polyzos A; Christou A; Kakolyris S; Kouroussis C; Androulakis N; Samonis G; Chatzidaki D
    J Clin Oncol; 2005 May; 23(13):2937-45. PubMed ID: 15728228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
    Kubota K; Kunitoh H; Seto T; Shimada N; Tsuboi M; Ohhira T; Okamoto H; Masuda N; Maruyama R; Shibuya M; Watanabe K
    Lung Cancer; 2020 Mar; 141():32-36. PubMed ID: 31931444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
    Sacristán JA; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
    Lung Cancer; 2000 May; 28(2):97-107. PubMed ID: 10717327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.